Could This New Weight-Loss Pill Disrupt the Entire Market? Here’s What You Should Know About Orforglipron

In a 52-week phase 3 trial of 1,698 adults with type 2 diabetes, once-daily orforglipron lowered HbA1c more than oral semaglutide.

Orforglipron also produced greater weight loss than the comparator drug.

The oral GLP-1, however, caused more gastrointestinal side effects and more treatment dropouts.

If confirmed in broader studies, an effective pill could expand access to diabetes and obesity treatment by reducing reliance on injections.